Alphatec Holdings Partners with Theradaptive to Transform Spinal Fusion with OsteoAdapt

Alphatec Holdings Partners with Theradaptive to Revolutionize Spinal Fusion Solutions

Alphatec Holdings, Inc. (Nasdaq: ATEC) solidifies its position as a frontrunner in spine surgery innovation through a strategic partnership with Theradaptive, Inc., a clinical-stage company focused on regenerative medicine. This collaboration grants ATEC exclusive rights to market Theradaptive's OsteoAdapt® osteoinductive bone graft for spinal fusion in the U.S., representing a notable leap in regenerative solutions within the spinal surgery sector. The agreement details a structured compensation model that combines upfront payments, milestone payments, and a perpetual royalty framework, designed to create substantial long-term value for both entities.

OsteoAdapt utilizes Theradaptive's proprietary AMP2™ protein technology and is currently in clinical trials for spinal and dental applications. The product's potential is underscored by three FDA Breakthrough Device Designations, indicating its promise to address critical medical needs in bone regeneration. ATEC's CEO, Pat Miles, emphasizes that this partnership not only enhances ATEC's procedural ecosystem but also aims to set a new standard for clinical outcomes in spinal fusion. The integration of OsteoAdapt into ATEC’s offerings is expected to improve patient outcomes significantly, leveraging advanced biologic solutions to complement existing surgical techniques.

To expedite the commercialization of OsteoAdapt, Theradaptive is launching a Series B investment round intended to fund the OASIS Pivotal trial and expand manufacturing capabilities. Luis Alvarez, Ph.D., Founder and CEO of Theradaptive, expresses confidence in the partnership, citing ATEC as the ideal collaborator to ensure the revolutionary technology reaches patients effectively. This strategic alignment is poised to catalyze innovation in regenerative medicine, driving advancements in spinal therapies and potentially transforming the landscape of spinal fusion surgery.

In addition to the partnership, ATEC's commitment to enhancing its procedural ecosystem reflects a broader trend in the spine industry toward integrating biologics with traditional surgical methods. By focusing on regenerative solutions, companies like ATEC and Theradaptive are addressing the growing demand for improved clinical outcomes in spinal procedures. This collaboration not only positions ATEC as a leader in the evolving market but also underscores the importance of innovation in improving patient care.

As the partnership unfolds, stakeholders in the spine industry watch closely, anticipating the potential impact of OsteoAdapt on spinal fusion practices. The convergence of innovative technologies and strategic collaborations signals a promising future for regenerative medicine in spine surgery, with ATEC at the forefront of this transformation.